



**WITH AGENTS IN**

North America

South America

United Kingdom

Europe

Australasia

Africa



# COVID-19 IgM/IgG Rapid Screening Test

Rapid Immunoassay for COVID-19 Infection



# FAST • RELIABLE • ACCURATE

IgG and IgM in whole blood, serum and plasma

Results in less than 20 minutes including sample preparation

High sensitivity & specificity

Venous wholeblood, venous serum or fingerprick wholeblood samples can be used for testing

Received provisional authorisation from the Health Sciences Authority (HSA) in Singapore

Manufactured under ISO 13485



**Manufacturer:** Camtech  
**Factory:** Singapore  
**Production Capacity:** 5.1.1c  
**Price point:**

## Certifications

ISO 13485  
 Export Authorisation  
 FDA – Phillipines  
 Export Health Science Authority Approval

Camtech Diagnostics has provided notification to the US FDA that the Camtech Covid-19 IgM/IgG rapid test kit has been validated, and will be distributed under the US FDA Guidance document titled "FDA Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency (issue March 16, 2020)

## References

[Mobi Health News](#)  
[Forbes](#)

## Recommended Markets:

USA  
 South America  
 Europe  
 Africa  
 Australasia




# COVID-19 TESTING

The coronavirus outbreak has swept across the Globe evolving into a pandemic as declared by the WHO on the 12 March 2020. Diagnosis has been at the forefront of monitoring the spread of the disease and ensuring timely treatment, especially, for those who are most at risk.

The currently employed method for diagnosis relies on RT-PCR to identify viral-specific nucleotides. Although accurate, this approach is both time and labour intensive, moreover, requiring specialist training and equipment. Therefore, there is a need for an easy to use, rapid testing approach to provide timely treatment and identification of post-infection immunity in mind or asymptomatic cases.

## ASSAY PROCEDURE & INTERPRETATION



*Note: Please read under bright light. Even a faint line in the test region is noted to be positive.*

## COMPARISON WITH MOLECULAR TESTING

	MOLECULAR TESTING (RT-PCR)	COVID-19 IgM/IgG RAPID SCREENING TEST
<b>Principle</b>	Nucleic acid test of SARS-CoV-2	Antibody IgM/IgG detection in blood
<b>Accuracy (field data)</b>	<ul style="list-style-type: none"> <li>• China: 30-50% (Jungangilbo 2020.02.13.)</li> <li>• Depending on the swab positioning of the specimen and yield of gene extraction</li> </ul>	<ul style="list-style-type: none"> <li>• Before Day 5: very low</li> <li>• After Day 5: 81-99% for IgM, 81-99% for IgG</li> </ul>
<b>Test time (incl. sample prep.)</b>	> 2 hours	20 minutes
<b>Test cost</b>	Very expensive	Highly economical
<b>Users</b>	Trained personnel	Untrained personnel
<b>Specimen</b>	Throat, nasopharyngeal swab, sputum	Whole blood, serum, plasma
<b>Advantages / Disadvantages</b>	<ul style="list-style-type: none"> <li>• Accurate at early stage</li> <li>• Difficult to detect latent stages of infection or post-infection.</li> <li>• Appropriate for early stage with limited cases of patients up to 100 patient load</li> </ul>	<ul style="list-style-type: none"> <li>• Possible to detect latent stages of infection or post-infection.</li> <li>• Appropriate 5 days after the onset of symptoms</li> <li>• Suitable for testing a large number of patients</li> </ul>

## DIAGNOSTIC ACCURACY

PARAMETERS	PERFORMANCE (ONGOING)
Analytical sensitivity (ELISA)	1.84 s/CO for IgM; 1.57 s/CO for IgG
Sensitivity	Day 3 after symptoms: IgM - 30%; IgG - 0% After Day 7 from symptoms: IgM 80%; IgG >95%
Specificity	99.5% (99% for IgM + 100% for IgG) after Day 7 from symptoms

## ORDERING INFORMATION

PRODUCT ID	PACKAGE	BOX SIZE (mm)
CAMTECH-COVID19IgG/IgMRAPIDTEST	20 tests / box	226 x 125 x 75

## BOX CONTENTS

- 20 pieces of test devices (foil-pouched)
- 1 dropping bottle of assay solution
- 25 capillary tubes for sample loading
- Instruction manual



# MGN Additional Products



3 Ply Protective




KN95



3 Ply Medical

# Contact global head of sales and partnership:



5.1.2e

Email: 5.1.2e @myglobalnetworks.com

Cell: +44

5.1.2e

Cell: +27

"With a hands on and resourceful team of experienced partners, **MYGLOBALNETWORK** has come together under the current COVID 19 crisis to source, market and assist with procurement and distribution of essential goods, globally."

5.1.2e

"At **MYGLOBALNETWORK** we realise the opportunity that currently exists to reshape the relationship between commerce and compassion. Our integrity, transparency and care for our neighbours (locally and abroad) will ensure sustainable and ethical business practice in our organisation."

5.1.2e

"**MYGLOBALNETWORK** has a global reach that puts us in six continents, over thirty prominent countries (including the Americas, United Kingdom, key African countries, Indian oceans and Europe). What really separates us though is that we are in contact with many government and health ministries, NHS, Scottish Health ministry, various African health ministries and key senior officials in North and South America to name a few. Our reach grows daily."

5.1.2e

"Although the biggest challenge we face currently is understanding (and authenticating) the various products that we see being brought on to the market to assist with and fight COVID 19, I do believe our greatest challenge, in time, would be to anticipate what the world is going to need moving forward. The true effects of COVID 19 are yet to be seen, **MYGLOBALNETWORK** is actively working on understanding and anticipating our planets needs, both commercial and humanitarian to ensure that we are ready for what may come."

5.1.2e

[www.myglobalnetworks.com](http://www.myglobalnetworks.com)

